



**IPSOGEN**  
CANCER PROFILER

# PRESS RELEASE

---

## IPSOGEN TO PRESENT A STUDY ON GENOMIC GRADE IN LOBULAR CARCINOMA AT THE 3RD IMPAKT BREAST CONFERENCE IN BRUSSELS, BELGIUM.

**Marseille, France, May 02, 2011** - IPSOGEN (Alternext – FR0010626028 - ALIPS), a cancer “profiler” that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, today announces that a study on Genomic Grade will be presented at the 3rd IMPAKT Breast Cancer Conference, taking place May 5-7, 2011, in Brussels, Belgium. The Genomic Grade test (GG), a multi-gene expression test, improves determination of tumor grade, a key parameter of long term prognosis in breast cancer. Consequently, the Genomic Grade test leads optimisation of treatment decisions for women with early invasive hormone receptor positive breast cancer.

This study, focusing on lobular carcinoma, a category of breast carcinoma in which tumor grading and establishment of long term prognosis are challenging, is based on a collaboration between Institut Jules Bordet, Belgium, Clinique Universitaire Saint Luc, Belgium, Institut Paoli Calmette, France and IPSOGEN. Results of the study show that even in a particularly difficult-to-characterise tumor type the Genomic Grade test significantly improves determination of tumor grade and therefore long term prognosis .

Poster # 33P: *" Genomic Grade Index improves tumor grading of invasive lobular breast carcinoma. "*

Presenter: Otto Metzger-Filho, Jules Bordet Institute, Brussels, Belgium

Friday, May 6, 2011, 16:20 – 17:00, selected posters walk, Gold Hall

### About Genomic Grade

The value of tumor grade as one of the key drivers for long term prognosis of hormone receptor positive early invasive breast cancer has been widely documented over the last decade and tumor grade is part of all current treatment guidelines and decision algorithms.

However, assessment of tumor grade, measured to date by histology, suffers two limitations: variability of assessment across pathology labs, and presence of an intermediate category, histologic grade 2, which can represent as much as 50% of tumors and has a limited informative power for treatment decision making.

The Genomic Grade test has been developed to address these 2 limitations. Proliferation genes are the main component of the selected gene signature. The added value of Genomic Grade to identify high and low grade tumors, esp. in histologic grade 2 tumors, has been documented on 3 000 cases. Moreover, Genomic Grade is able to separate Luminal A and Luminal B tumors.

In 2009, the Genomic Grade test has been integrated to St Gallen international guidelines as an adjunct to histological grading.



**IPSOGEN**  
CANCER PROFILER

# PRESS RELEASE

Genomic Grade is currently available as MapQuant™, an Affymetrix micro-array based assay. A PCR version is currently under development, that will allow testing of formalin fixed-paraffin embedded specimens.

## About Invasive Lobular Carcinoma

Invasive lobular carcinoma, which represents approx. 10% of invasive breast carcinoma, is the second most common histologic type after ductal carcinoma. Its management and treatment modalities are similar to those of ductal carcinoma.

However, because of the specific abnormalities characterising lobular carcinoma cells, it is particularly difficult to reliably measure tumor grade with the standard histologic tools. Moreover, up to 80% of lobular carcinoma are classified as histologic grade 2, an intermediate grade category of limited informative value. It is therefore difficult to apply the well-validated treatment decision algorithms –most of them incorporating tumor grade– for this category of breast carcinoma.

## About IPSOGEN

IPSOGEN, cancer profiler, develops and markets molecular diagnostic tests that help to map diseases and guide patients and oncologists' decisions along their therapeutic path. With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukaemia, IPSOGEN is now targeting breast cancer with the aim of providing currently inaccessible diagnostic information.

Strengthened by its scientific, clinical and technological partnerships, and by its multidisciplinary team in France and the USA, IPSOGEN plans to become a world leader in the molecular profiling of cancers, and to continue the development and promotion of best-in-class diagnostic references that have a significant impact on patients, medical professionals and society. The company headquarters are located in Marseilles , France. Ipsogen has a subsidiary, IPSOGEN Inc., in Stamford, CT, USA.

For further information, please visit us at: [www.ipsogen.com](http://www.ipsogen.com)

## Contacts

---

### IPSOGEN

#### Vincent Fert

CEO

Tél : + 33 (0)4 9129 3090

[fert@ipsogen.com](mailto:fert@ipsogen.com)

#### Hélène Peyro-Saint-Paul

CMO

Tél : + 33 (0)4 9129 3090

[peyro-saint-paul@ipsogen.com](mailto:peyro-saint-paul@ipsogen.com)

#### Pascale Boissel

CFO

Tél : + 33 (0)4 9129 3090

[pascale.boissel@ipsogen.com](mailto:pascale.boissel@ipsogen.com)

#### ATCG-Press

Corporate and Product  
Information

#### Marielle Bricman

Tél : + 33 (0)4 9125 0785

[ipsogen@atcg-partners.com](mailto:ipsogen@atcg-partners.com)

#### NewCap

Financial communication and  
Investor relations

#### Axelle Vuillermet & Pierre Laurent

Tél : + 33 (0)1 44 71 94 93

[ipsogen@newcap.fr](mailto:ipsogen@newcap.fr)

**ALIPS**  
**LISTED**  
**NYSE**  
**ALTERNEXT**